Feinberg Cardiovascular Research Institute, Northwestern University School of Medicine and Northwestern Memorial Hospital, Chicago, Illinois 60611, USA.
J Nucl Med. 2010 May 1;51 Suppl 1(Suppl 1):122S-127S. doi: 10.2967/jnumed.109.068304. Epub 2010 Apr 15.
Ischemic cardiovascular diseases cause a significant burden of morbidity and mortality throughout the world. Over the past decade, we have learned a tremendous amount about the biology of various stem and progenitor cells. Multiple preclinical experiments have demonstrated significant bioactivity in a wide variety of stem and progenitor cells. Early clinical trials have also shown some promising results. This review will focus on the current challenges in the translation of cell therapy to a viable clinical therapy. Additionally, we will highlight the role of cardiovascular imaging and molecular imaging in the future of stem cell therapy.
缺血性心血管疾病在全球范围内造成了巨大的发病率和死亡率负担。在过去的十年中，我们对各种干细胞和祖细胞的生物学特性有了深入的了解。多项临床前实验表明，多种干细胞和祖细胞具有显著的生物活性。早期临床试验也取得了一些有希望的结果。本文将重点讨论将细胞疗法转化为可行的临床治疗所面临的挑战。此外，我们还将强调心血管成像和分子成像在干细胞治疗未来中的作用。
